Is Beam Therapeutics (NASDAQ:BEAM) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Beam Therapeutics at current levels.
Beam's base editing platform is approaching its first real clinical readouts with enough cash to get there, and the market still prices it like science fiction.
Where BEAM is headed
By the end of 2027, Beam Therapeutics (NASDAQ:BEAM) will either be one of the most validated genetic medicine companies on the planet or a cautionary tale about platform bets that never translated to patients. The gap between those outcomes is enormous, and the stock's current $3.3 billion market cap sits awkwardly in the middle, pricing in some probability of success but deeply discounting the breadth of the pipeline. Here's what's actually changing: risto-cel (their autologous base-edited stem cell therapy for sickle cell disease) is now generating clinical data that should mature into pivotal readouts over the next 12-18 months, while their liver-targeting LNP programs (BEAM-302 for alpha-1 antitrypsin deficiency, BEAM-301 for GSD1a) are in dose-escalation studies that will reveal whether in vivo base editing works in humans at therapeutically meaningful levels. These are not incremental improvements to existing drugs. They're attempts to permanently fix broken genes inside a living person.
Read the full Compass Direction on BEAM
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $30.47).
See the full BEAM analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Beam Therapeutics (NASDAQ:BEAM) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Beam Therapeutics at current levels. Beam's base editing platform is approaching its first real clinical readouts with enough cash to get there, and the market still prices it like science fiction.
What is BEAM's Compass Score?
Beam Therapeutics scores 90/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for BEAM?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the BEAM page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.